Overview

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
Phase:
Phase 4
Details
Lead Sponsor:
Canyon Pharmaceuticals, Inc.
Treatments:
Desirudin
Heparin
Hirudins